Novel homologated-apio adenosine derivatives as A3 adenosine receptor agonists: Design, synthesis and molecular docking studies

dc.contributor.authorPanda A.en_US
dc.contributor.authorSatpati S.en_US
dc.contributor.authorDixit A.en_US
dc.contributor.authorPal S.en_US
dc.date.accessioned2025-02-17T05:43:43Z
dc.date.issued2016
dc.description.abstractSynthesis of a series of novel homologated-apio adenosine analogues including homologated-apio IB-MECA and Cl-IB-MECA has been accomplished from a commercially available, inexpensive starting material d-ribose. The synthetic route includes a controlled oxidative cleavage of vicinal diol and Mitsunobu condensation reactions as the key steps. The molecular docking studies of the synthesized compounds to the A3 adenosine receptor model indicated them as agonists. Interestingly, some of the molecules showed good binding interactions at the active site as evident by docking scores and MM/GBSA binding affinity. � 2016 The Royal Society of Chemistry.en_US
dc.identifier.citation4en_US
dc.identifier.urihttp://dx.doi.org/10.1039/c5ra26416b
dc.identifier.urihttps://idr.iitbbs.ac.in/handle/2008/1197
dc.language.isoenen_US
dc.titleNovel homologated-apio adenosine derivatives as A3 adenosine receptor agonists: Design, synthesis and molecular docking studiesen_US
dc.typeArticleen_US

Files